Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ifosfamide
Drug ID BADD_D01133
Description Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Indications and Usage Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
Marketing Status approved
ATC Code L01AA06
DrugBank ID DB01181
KEGG ID D00343
MeSH ID D007069
PubChem ID 3690
TTD Drug ID D02TLO
NDC Product Code 10019-925; 57884-0006; 63323-142; 0143-9531; 0338-3991; 15308-0411; 0338-3993; 65124-0001; 0143-9530; 10019-926; 10019-927; 10019-929
UNII UM20QQM95Y
Synonyms Ifosfamide | Isofosfamide | Isophosphamide | Iphosphamide | Iso-Endoxan | Iso Endoxan | Holoxan | NSC-109,724 | NSC 109,724 | NSC109,724 | NSC-109724 | NSC 109724 | NSC109724 | Asta Z 4942
Chemical Information
Molecular Formula C7H15Cl2N2O2P
CAS Registry Number 3778-73-2
SMILES C1CN(P(=O)(OC1)NCCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Unresponsive to stimuli17.02.05.0310.000112%-
Urethral disorder20.07.01.002---
Urinary incontinence17.05.01.008; 20.02.02.0100.000168%
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001---
Urticaria10.01.06.001; 23.04.02.001--
Vasculitis10.02.02.006; 24.12.04.027--
Venoocclusive liver disease09.01.06.002; 12.02.09.039; 24.04.07.002--
Ventricular arrhythmia02.03.04.006--
Ventricular extrasystoles02.03.04.007---
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013---
Vital capacity decreased13.19.01.002---
Vomiting07.01.07.0030.000750%
Mental status changes19.07.01.0010.000224%-
Tubulointerstitial nephritis20.05.02.0020.000280%-
Cardiotoxicity02.11.01.009; 12.03.01.0070.000112%-
Myocardial haemorrhage02.04.02.018; 24.07.01.035---
Hypoacusis04.02.01.006--
Brain oedema12.01.10.010; 17.07.02.0030.000112%
General physical health deterioration08.01.03.018---
Tumour haemorrhage16.32.03.008; 24.07.01.0280.000112%
Balance disorder08.01.03.081; 17.02.02.0070.000112%-
Bradyphrenia17.03.03.004; 19.10.03.002---
Ejection fraction decreased13.14.02.003--
Deep vein thrombosis24.01.02.0030.000112%-
Hyperphosphaturia14.04.03.006; 20.02.01.025---
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene